What are the history, physical examination findings, and clinical features of pheochromocytoma?

Clinical Features of Pheochromocytoma

Suspect pheochromocytoma in any hypertensive patient presenting with the classic triad of headaches, palpitations, and sweating occurring episodically, which has 90% diagnostic specificity. 1

Key Historical Features

Classic Symptom Triad

• Headaches, palpitations, and sweating occurring in episodic fashion constitute the hallmark presentation with 90% specificity 1
• These symptoms typically occur in paroxysmal episodes rather than continuously 1
• Approximately 95% of patients demonstrate hypertension (either sustained or paroxysmal) 1

Hypertension Patterns

• 50% present with sustained hypertension while the remainder have paroxysmal episodes 1
• Hypertension occurs in approximately 70% of all pheochromocytoma cases 1
• Characterized by marked blood pressure variability, which independently increases cardiovascular morbidity and mortality risk beyond elevated pressure alone 1
• The degree of blood pressure variability correlates with norepinephrine secretion levels 1

Additional Symptoms

• Pallor during hypertensive episodes 1
• Anxiety attacks 2
• Syncope or cardiac arrest in severe cases 1
• Some patients may be entirely asymptomatic, particularly in familial cases 3

Physical Examination Findings

Cardiovascular Signs

• Sustained or paroxysmal hypertension is the predominant finding 1, 4
• Tachycardia during symptomatic episodes 5
• Signs of hypertensive end-organ damage may be present 1

Important Caveat

Many pheochromocytomas present with atypical or minimal physical findings, making the diagnosis challenging 5, 6. The clinical presentation is highly variable and can mimic numerous other conditions 4.

Epidemiology and Risk Context

• Prevalence is 0.1-0.6% in general hypertensive populations 1
• Represents 0.2-0.4% of all secondary hypertension cases 1
• Average delay from symptom onset to diagnosis is 3 years 1
• Autopsy studies reveal that 75% of cases were not suspected clinically, and the tumors contributed to 55% of deaths 1

High-Risk Populations Requiring Screening

Clinical Indications 5

• Paroxysmal, resistant, or early-onset arterial hypertension
• Symptoms suggestive of catecholamine hypersecretion
• Adrenal incidentalomas with >10 Hounsfield Units on non-contrast CT
• Diabetes mellitus with atypical presentation

Hereditary Syndromes 1

• Neurofibromatosis type 1 (NF1): Consider screening in hypertensive patients over age 30, pregnant patients, or those with paroxysmal hypertension
• Multiple Endocrine Neoplasia type 2 (MEN2)
• Von Hippel-Lindau syndrome (VHL)
• SDHx gene mutations (SDHA, SDHB, SDHC, SDHD, SDHAF2)
• TMEM127 and MAX gene mutations

Special Considerations in NF1

• Incidence of 0.1-5.7% in NF1 patients; 22% are asymptomatic 1
• Median age of presentation is 43 years (range 14-61 years) 1
• Exclusively adrenal disease (no paragangliomas); 20% multifocal, 12% malignant 1

Critical Diagnostic Pitfall

The most important clinical message is to think of pheochromocytoma 4. The diagnosis is frequently missed because it is not considered, leading to devastating cardiovascular complications or death 3. The wide variability in presentation means that any patient with unexplained hypertension, particularly if paroxysmal or resistant to treatment, warrants biochemical screening 5, 6.

Biochemical Screening Recommendation

Plasma free metanephrines (normetanephrine and metanephrine) is the best screening test, with 99% sensitivity and 89% specificity 1. This should be the initial test when pheochromocytoma is suspected clinically 1.